KITASAMYCIN TARTRATE

Kitasamycin tartrate is a tartrate salt form of kitasamycin providing improved solubility and formulation stability with the same macrolide mechanism. Benefits mirror those of kitasamycin in treating susceptible infections. Side effects include GI upset, altered liver function tests, and allergic skin reactions in some patients.

SKU: 09138eb50086 Category: Tag:

Product Description


Mechanism of Action

KITASAMYCIN TARTRATE (ID 26503) exhibits a structured and multi‑layered biochemical activity profile involving modulation of enzymatic cascades, receptor‑binding dynamics, intracellular signalling architecture, and metabolic‑flux regulation. Its molecular characteristics indicate potential interactions with catalytic pockets, allosteric surfaces, and regulatory protein domains. Through these interactions, the compound influences phosphorylation patterns, mitochondrial bioenergetics, oxidative‑stress networks, membrane potential stabilization, and transcriptional pathway responsiveness.

In cellular systems, mechanistic effects may include modulation of calcium flux, ROS equilibrium, structural‑protein turnover, and adaptive stress‑response activation. The compound may act as a pathway booster, suppressor, or modulator depending on dosing, cellular environment, and metabolic state.

Benefits and Advantages

This compound is widely used in biochemical, pharmacological and mechanistic research settings, including:

  • Receptor‑ligand interaction studies and affinity‑mapping assays
  • Enzyme kinetics and catalytic‑pathway modelling
  • Mitochondrial‑function, ROS‑regulation and redox‑balance experiments
  • Transcriptomic, proteomic and metabolomic profiling
  • Cell‑stress signalling, apoptosis/autophagy pathway mapping and cytoskeletal‑dynamics studies
  • Pharmacodynamic simulation and SAR (structure‑activity relationship) analysis

Side Effects and Risks

Risks may include unintended oxidative imbalance, mitochondrial overload, receptor cross‑talk effects, disruption of ion‑channel homeostasis, and dose‑dependent cytotoxicity. At elevated concentrations, the compound may trigger apoptosis, autophagy, or compensatory metabolic rewiring. Long‑term exposure can influence transcriptional stability, signalling thresholds, and cellular resilience.

Use only in controlled laboratory environments following strict biosafety and handling protocols. Not intended for human or veterinary use.

Datasheet


Molecular Formula

C40H67NO18

Molecular Weight

850.0 g/mol

CAS Number

37280-56-1

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

kitasamycin tartrate; 37280-56-1; IPN75MD9DR; Leucomycin, (R-(R*,R*))-2,3-dihydroxybutanedioate (salt); Leucomycin, [R-(R*,R*)]-2,3-dihydroxybutanedioate (salt)

IUPAC/Chemical Name

2,3-dihydroxybutanedioic acid;2-[(4R,5S,6S,7R,9R,10R,11E,13E,16R)-6-[(2S,3R,4R,5S,6R)-4-(dimethylamino)-3-hydroxy-5-[(2R,5S,6R)-5-hydroxy-4,4,6-trimethyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde

InChl Key

LCDBILLRZFJKMN-RKYMYSRXSA-N

InChl Code

InChI=1S/C36H61NO12.C4H6O6/c1-20-17-24(15-16-38)32(33(44-9)26(40)18-27(41)45-21(2)13-11-10-12-14-25(20)39)49-35-30(42)29(37(7)8)31(22(3)47-35)48-28-19-36(5,6)34(43)23(4)46-28;5-1(3(7)8)2(6)4(9)10/h10-12,14,16,20-26,28-35,39-40,42-43H,13,15,17-19H2,1-9H3;1-2,5-6H,(H,7,8)(H,9,10)/b11-10+,14-12+;/t20-,21-,22-,23-,24+,25+,26-,28-,29-,30-,31-,32+,33+,34-,35+;/m1./s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/6450271;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download